We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure coreplatform@cambridge.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
This concise, yet authoritative, clinical reference guide fulfils the needs of diverse clinicians, pharmacists and allied health professionals prescribing for Parkinson's disease and movement disorders in contemporary clinical practice. With chapters on newly approved drugs and their effects on motor and non-motor symptoms, information is also given on their use in particular populations including the elderly and patients with cognitive impairment. Each chapter includes pharmacological/biochemical rationale for drug use, a general guide to therapeutic use, pharmacokinetics, interaction profile, adverse effects, dosing and use, special population considerations, costs and value for money considerations, clinical vignette, a summary overview, and suggested reading. Ordered alphabetically and perfect for quick reference use, the guide is practical and essential for all prescribers with responsibility for patients with Parkinson's disease, including neurologists, geriatricians, internists, neurosurgeons, psychiatrists, family physicians, pharmacists as well as allied health professionals and resident, fellow, and student trainees in all related medical fields.
Non-motor symptoms (NMS) are a crucial component of Parkinson’s disease (PD) and the burden of the range of NMS that occurs in PD is one of the main determinants of quality of life [1]. In 1817, Dr. James Parkinson already described several NMS in his “shaking palsy,” the condition that would later be named after him, including pain, constipation, and sleep disturbances [2]. Nonetheless, after a long period of inertia, over the last 20 to 25 years, the interest in NMS has increased and evidence suggests that the overall burden of NMS dominates and can influence the risk of developing motor parkinsonism in the premotor stage of PD while being a driving factor for quality of life [3]. The identification of NMS in PD has been greatly aided by the development of specific tools, such as the NMS questionnaire (NMSQ) in 2006 [4] and the NMS Scale (NMSS) in 2007 [5].
Recommend this
Email your librarian or administrator to recommend adding this to your organisation's collection.